Replies to post #852 on Nephros Inc (NEPH)

[docmts2]

Sorry to hear that, Smokey.

[mikeyk]

Calm down smokey, you haven't lost anything until you sell, it's a paper loss right now, and it's not over yet. The company hired a very expensive high powered law firm when it received it's NSE, and on the 4th of July Holiday weekend to boot. NEPH isn't a one trick pony, they have other products they sell which can take them cash flow positive. The filter that was determined "not substantially equivalent" is being sold in Europe, Japan, and Canada, all of them approved this filter. The problem is not with the filter, the problem is in the filing, which means the company may need to refile to make the FDA happy. We won't know until the company has it's sit down face to face meeting with the FDA and the expensive high powered lawyer for what comes next. This isn't a fly by night law firm, they have some very large and influential clients:


3M
Arcapita Bank B.S.C.
Bank of America
Baxter International
Boehringer Ingelheim
Chevron USA
ChoicePoint, Inc.
CitiGroup – CitiBank
The Coca-Cola Company
Cooper Industries
Credit Suisse Securities
CVS Caremark Corporation
Delta Airlines
Duke Energy Corporation
Eli Lilly
Ernst & Young
Equifax
Eurx Properties SCA
Exxon Mobil Corporation
General Electric Company
General Motors Corporation
Georgia-Pacific Corporation
GlaxoSmithKline
Goldman Sachs
Google
HDG Mansur Investment Services Inc.
Hoffman-LaRoche
The Home Depot
Honeywell International Inc.
IBM
IVG Institutional Funds GmbH
Johnson & Johnson
KPMG
Lockheed Martin Corporation
MillerCoors
Morgan Stanley Capital Group, Inc.
Mubadala Development Corporation
Nokia Corporation
Pfizer
PricewaterhouseCoopers
Prudential Capital Group
Purdue Pharma L.P.
Roark Capital Group
RJ Reynolds
Sanofi-Aventis
Shell Oil Company
Sprint Nextel Corporation
SunTrust Banks, Inc.
UCB, Inc.
UPS
Wachovia / Wells Fargo
Walmart
WellCare Health Plans, Inc.